17 Publications
2021
Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla, Nikhil AtulAlthouse, SandraMeyer, ZacharyHanna, Nasser and Durm, Greg
Clinical lung cancer, January 23, 2021. | Journal Article
2020
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
Swiecicki, Paul LDurm, GregBellile, EmilyBhangale, ApurvaBrenner, J Chad and Worden, Francis P
Investigational new drugs, 2020-Jan-24. | Journal Article
 
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
Durm, Greg ADurm, Greg ADurm, Greg ADurm, Greg ADurm, Greg AJabbour, Salma KJabbour, Salma KJabbour, Salma KJabbour, Salma KJabbour, Salma KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KLiu, ZiyueLiu, ZiyueLiu, ZiyueLiu, ZiyueLiu, ZiyueSadiq, Ahad ASadiq, Ahad ASadiq, Ahad ASadiq, Ahad ASadiq, Ahad AZon, Robin TZon, Robin TZon, Robin TZon, Robin TZon, Robin TJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JReckamp, Karen LReckamp, Karen LReckamp, Karen LReckamp, Karen LReckamp, Karen LLangdon, Robert MLangdon, Robert MLangdon, Robert MLangdon, Robert MLangdon, Robert MKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AHarb, Wael AHarb, Wael AHarb, Wael AHarb, Wael AHarb, Wael AWalling, Radhika VWalling, Radhika VWalling, Radhika VWalling, Radhika VWalling, Radhika VTitzer, Michael LTitzer, Michael LTitzer, Michael LTitzer, Michael LTitzer, Michael LHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Cancer, vol. 126, (no. 19), pp. 4353-4361, Oct 2020. | Journal Article
 
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179
Anouti, BilalAnouti, BilalAlthouse, SandraAlthouse, SandraDurm, GregDurm, GregHanna, Nasser and Hanna, Nasser
Clinical Lung Cancer, vol. 21, (no. 3), pp. 293, May 2020. | Journal Article
2019
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence
Nguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanh and Ceppa, DuyKhanh
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 6578, 2019-05-20. | Journal Article
 
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081
Yan, MelissaYan, MelissaDurm, Greg AndrewDurm, Greg AndrewMamdani, HirvaMamdani, HirvaGanti, Apar KishorGanti, Apar KishorHrinczenko, BorysHrinczenko, BorysJabbour, Salma KJabbour, Salma KFeldman, Lawrence EricFeldman, Lawrence EricKloecker, Goetz HKloecker, Goetz HLeal, TicianaLeal, TicianaAlmokadem, SalahAlmokadem, SalahNaidoo, JarushkaNaidoo, JarushkaFujioka, NaomiFujioka, NaomiHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 8535, 2019-05-20. | Journal Article
 
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)
Durm, GregDurm, GregHanna, Nasser and Hanna, Nasser
Translational Lung Cancer Research, vol. 8, (no. 4), pp. 542, 2019-08-00. | Journal Article
2018
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081
Durm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewPerkins, Susan MPerkins, Susan MPerkins, Susan MHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. TPS179, 2018-02-10. | Journal Article
 
Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection
Durm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewPerkins, SusanPerkins, SusanPerkins, SusanJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimKong, Feng-Ming (Spring)Kong, Feng-Ming (Spring)Kong, Feng-Ming (Spring)Birdas, Thomas JBirdas, Thomas J and Birdas, Thomas J
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 8513, 2018-05-20. | Journal Article
 
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179
Durm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KSadiq, Ahad AliSadiq, Ahad AliSadiq, Ahad AliJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJabbour, SalmaJabbour, SalmaJabbour, SalmaZon, RobinZon, RobinZon, RobinKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HFisher, William BFisher, William BFisher, William BReckamp, Karen LReckamp, Karen LReckamp, Karen LKio, Ebenezer AKio, Ebenezer AKio, Ebenezer ALangdon, Robert MLangdon, Robert MLangdon, Robert MAdesunloye, BamideleAdesunloye, BamideleAdesunloye, BamideleGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 8500, 2018-05-20. | Journal Article
 
Potential risk factors of pneumonitis associated with consolidation pembrolizumab after chemoradiation in unresectable NSCLC patients
Ahmed, Shahid SattarAhmed, Shahid SattarAhmed, Shahid SattarDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDonatelli, JohnDonatelli, JohnDonatelli, JohnYao, HuanYao, HuanYao, HuanLiu, YongmeiLiu, YongmeiLiu, YongmeiDesRosiers, ColleenDesRosiers, ColleenDesRosiers, ColleenLiu, ZiyueLiu, ZiyueLiu, ZiyueKong, Feng MingKong, Feng MingKong, Feng MingHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. 167, 2018-02-10. | Journal Article
2017
Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Cheng, MonicaCheng, MonicaCheng, MonicaDurm, GregDurm, GregDurm, GregHanna, NasserHanna, NasserHanna, NasserEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HKong, Feng-Ming (Spring)Kong, Feng-Ming (Spring) and Kong, Feng-Ming (Spring)
Future Oncology, vol. 13, (no. 28), pp. 2505, 2017-December-01. | Journal Article
 
Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179
Durm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewJohnson, CynthiaJohnson, CynthiaJohnson, CynthiaJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimSadiq, Ahad AliSadiq, Ahad AliSadiq, Ahad AliJabbour, SalmaJabbour, SalmaJabbour, SalmaZon, RobinZon, RobinZon, RobinKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HReckamp, Karen LReckamp, Karen LReckamp, Karen LFisher, William BFisher, William BFisher, William BHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 35, (no. 15_suppl), pp. 8523, 2017-05-20. | Journal Article
2016
Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179
Durm, Greg AndrewDurm, Greg AndrewKio, Ebenezer AKio, Ebenezer AFisher, William BFisher, William BTitzer, Michael LTitzer, Michael LJabbour, SalmaJabbour, SalmaBreen, TIMBreen, TIMLiu, ZiyueLiu, ZiyueHanna, Nasser H and Hanna, Nasser H
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. e20025, 2016-05-20. | Journal Article
 
Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU)
Tatineni, SushmaTatineni, SushmaTatineni, SushmaDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewKunapareddy, Girish ChandraKunapareddy, Girish ChandraKunapareddy, Girish ChandraAmmakkanavar, Natraj ReddyAmmakkanavar, Natraj ReddyAmmakkanavar, Natraj ReddyDropcho, Edward FDropcho, Edward FDropcho, Edward FAlthouse, SandraAlthouse, SandraAlthouse, SandraHanna, Nasser HHanna, Nasser HHanna, Nasser HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HAlbany, CostantineAlbany, Costantine and Albany, Costantine
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. e16052, 2016-05-20. | Journal Article
2015
An update on current standards and clinical trials in systemic therapy for stage III NSCLC
Durm, GregDurm, GregHanna, Nasser and Hanna, Nasser
Lung Cancer Management, vol. 4, (no. 6), pp. 297, 2015-December-01. | Journal Article
2014
Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer
Durm, GregDurm, GregHanna, Nasser and Hanna, Nasser
Future Oncology, vol. 10, (no. 7), pp. 1173, 2014-May-01. | Journal Article